Radioactive beads given through an artery for pancreatic cancer that cannot be removed
Tests yttrium-90 radioactive beads in adults with pancreatic cancer that cannot be removed.
Plain-language title generated from the registry record
Registry title: A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer
Key facts
- Where
- Obninsk, RussiaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07898683, who can take part
Where in Russia
- Medical Radiological Research Center named after A.F. Tsyb (MRRC) - National Medical Research Center of RadiologyObninsk, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Medical Research Radiological Centre of the Ministry of Health of Russia
- Trial code
- NCT07898683
- Record updated
- 27 October 2026
- Original description
This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma. The study will assess radiation dose distribution, adverse effects, and preliminary efficacy following selective arterial radioembolization.Read full original descriptionShow less
Selective Intra-Arterial Yttrium-90 Radioembolization for the Treatment of Unresectable Pancreatic Adenocarcinoma: A Phase I Clinical Trial
This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma. The study will assess radiation dose distribution, adverse effects, and preliminary efficacy following selective arterial radioembolization.
Inclusion: Histologically confirmed pancreatic adenocarcinoma (T4N0/1M0/1); ECOG performance status 0-1, for at least 2 weeks; Life expectancy ≥12 weeks; Signed informed consent for participation.
Exclusion: Prior solid organ transplant; Active gastrointestinal ulcers or recent GI bleeding (<3 months); Active Hepatitis B/C or other significant infectious disease; Uncontrolled cardiovascular disease (NYHA class III/IV heart failure, recent MI, severe arrhythmias); Any condition deemed by investigators as unsafe for participation; Significant haematological abnormalities (ANC <1.5×10⁹/L, platelets <100×10⁹/L, haemoglobin <8 g/dL); Severe hepatic dysfunction (total bilirubin >1.5×ULN, ALT/AST >4×ULN without liver metastases); ECOG >2 or Karnofsky score <60%; Pregnancy or lactation.